Comparative assessment of the cost-effectiveness of Tuberculosis (TB) active case-finding interventions: A systematic analysis of TB REACH wave 5 projects
Open Access
- 26 September 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0270816
Abstract
Purpose: Interventions that can help streamline and reduce gaps in the tuberculosis (TB) care cascade can play crucial roles in TB prevention and care, but are often operationally complex and resource intensive, given the heterogenous settings in which they are implemented. In this study, we present a comparative analysis on cost-effectiveness of TB REACH Wave 5 projects with diverse programmatic objectives to inform future decisions regarding funding, strategic adoption, and scale-up. Methods: We comprehensively reviewed project reports and financial statements from TB REACH Wave 5, a funding mechanism for interventions that aimed to strengthen the TB care cascade in diverse settings. Two independent reviewers abstracted cost (in 2017 US dollars) and key programmatic data, including project type (case-finding only; case-finding and linkage-to-care; or case-finding, linkage-to-care and patient support), operational setting (urban or rural), and project outputs (numbers of people with TB diagnosed, started on treatment, and successfully completing treatment). Cost-effectiveness ratios for each project were calculated as ratios of apportioned programmatic expenditures to corresponding project outputs. Results: Of 32 case finding and patient support projects funded through TB REACH Wave 5, 29 were included for analysis (11 case-finding only; 9 case-finding and linkage-to-care; and 9 case-finding, linkage-to-care and patient support). 21 projects (72%) were implemented in either Africa or Southeast Asia, and 19 (66%) focused on serving urban areas. Average cost-effectiveness was $184 per case diagnosed (range: $30-$10,497), $332 per diagnosis and treatment initiation ($123-$10,608), and $40 per patient treatment supported ($8-$160). Cost per case diagnosed was lower for case-finding-only projects ($132) than projects including linkage-to-care ($342) or linkage-to-care and patient support ($254), and generally increased with the corresponding country’s per-capita GDP ($543 per $1000 increase, 95% confidence interval: -$53, $1138). Conclusion: The costs and cost-effectiveness of interventions to strengthen the TB care cascade were heterogenous, reflecting differences in context and programmatic objective. Nevertheless, many such interventions are likely to offer good value for money. Systematic collection and analysis of cost-effectiveness data can help improve comparability, monitoring, and evaluation.Keywords
Funding Information
- Global Affairs Canada (CA-3-D000920001)
- Bill and Melinda Gates Foundation (OPP1139029)
This publication has 16 references indexed in Scilit:
- Disease Control Priorities, Third Edition (Volume 6): Major Infectious Diseases2017
- Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further ResearchValue in Health, 2016
- Turning off the tap: stopping tuberculosis transmission through active case-finding and prompt effective treatmentThe Lancet, 2015
- Thresholds for the cost–effectiveness of interventions: alternative approachesBulletin of the World Health Organization, 2014
- How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and IndiaBMC Medicine, 2014
- Timing of Tuberculosis Transmission and the Impact of Household Contact Tracing. An Agent-based Simulation ModelAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Results from early programmatic implementation of Xpert MTB/RIF testing in nine countriesBMC Infectious Diseases, 2014
- Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniaebacteremia in TaiwanBMC Infectious Diseases, 2014
- Active case finding for tuberculosis among high-risk groups in low-incidence countries [State of the art series. Case finding/screening. Number 3 in the series]The International Journal of Tuberculosis and Lung Disease, 2013
- A Systematic Review of Reported Cost for Smear and Culture Tests during Multidrug-Resistant Tuberculosis TreatmentPLOS ONE, 2013